Related Experiment Videos
Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha
1Section of Neuromuscular Disorders, Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA. mmeriggi@neuro.rush.edu
Muscle & Nerve
|February 19, 2000
Summary
Interferon-alpha treatment can trigger autoimmune disorders like chronic inflammatory demyelinating polyneuropathy (CIDP). A patient with hepatitis C achieved full remission of CIDP after stopping interferon and undergoing plasma exchange.
Area of Science:
- Immunology
- Neurology
- Hepatology
Background:
- Interferon-alpha (IFN-alpha) therapy is known to induce autoimmune conditions.
- Chronic viral hepatitis C infection is a prevalent condition often treated with IFN-alpha.
- Autoimmune disorders can manifest during or after IFN-alpha treatment.
Observation:
- A patient with chronic hepatitis C developed chronic inflammatory demyelinating polyneuropathy (CIDP) while receiving a novel, long-acting IFN-alpha formulation.
- The patient's neurological symptoms significantly worsened during the interferon therapy.
Findings:
- Discontinuation of IFN-alpha treatment was followed by a single course of plasma exchange.
- The patient experienced a complete clinical remission of CIDP symptoms after plasma exchange.
- No relapse of CIDP symptoms was observed post-treatment.
Implications:
- This case highlights a potential link between long-acting IFN-alpha and CIDP development in hepatitis C patients.
- Plasma exchange may be an effective treatment for IFN-alpha-induced CIDP.
- Further research is warranted to understand the mechanisms of IFN-alpha-associated autoimmunity and its management.